^
    Back
    Association details:
    Biomarker:HER-2 YVMA
    Cancer:Lung Cancer
    Drug:Pozenveo (poziotinib) (pan-EGFR inhibitor)
    Drug Class:HER2-targeted CAR-T immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

    Excerpt:
    ...NSCLC with documented HER2 exon 20 mutation by a...
    Trial ID:
    NCI-2017-00831
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    891 / 6 - CD70-targeting CAR-T and CAR-NK cells demonstrate potent activity against NSCLC drug-tolerant persister cells

    Published date:
    03/15/2023
    Excerpt:
    In a patient-derived xenograft model of HER2YVMA mutant lung cancer, we observed that HER2 CAR-NK cells showed enhanced antitumor activity in mice treated with the HER2 inhibitor, poziotinib, for two weeks, compared to CAR-NK cells only, poziotinib only, or mice treated upfront with HER2 CAR-NK cells plus poziotinib.